Pleiotropic effects of the non-calcium phosphate binder sevelamer

被引：37

作者：

Nikolov, I. G.

Joki, N.

Maizel, J.

Lacour, B.

Drueke, T. B.

Massy, Z. A.

机构：

[1] Amiens Univ Hosp, INSERM, ERI12, Div Clin Pharmacol, F-80054 Amiens, France

[2] Univ Picardie, INSERM, ERI12, Amiens, France

[3] Univ Paris 05, Necker Hosp, INSERM, U507, Paris, France

[4] Univ Paris 05, Necker Hosp, Biochim Lab A, Paris, France

来源：

KIDNEY INTERNATIONAL | 2006年 / 70卷

关键词：

D O I：

10.1038/sj.ki.5001994

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The number of chronic kidney disease (CKD) patients and related adverse outcomes has dramatically increased worldwide in the past decade. Therefore, numerous experimental and clinical studies have recently addressed the underlying mechanisms, in particular the marked increase in cardiovascular mortality. Hyperphosphatemia is a major problem in these patients with advanced stage of CKD. Its control by calcium-containing phosphate binders is effective, but at the price of potentially noxious calcium overload. Sevelamer hydrochloride is a phosphate binder that offers an effective control of hyperphosphatemia as calcium-rich binders but without increase of calcium load. Beyond the control of phosphate, sevelamer seems to exert pleiotropic effects which include the correction of lipid abnormalities and the clearance of some uremic toxins.

引用

页码：S16 / S23

页数：8

共 55 条

[1]

[Anonymous], KIDNEY INT S

[2]

[Anonymous], [No title captured]

[3] Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients [J].